High-relaxivity contrast-enhanced magnetic resonance neuroimaging: a review
Authors:
- 23 June 2010
- journal article
- review article
- Published by Springer Nature in European Radiology
- Vol. 20 (10) , 2461-2474
Abstract
Evaluation of brain lesions using magnetic resonance imaging (MRI) provides information that is critical for accurate diagnosis, prognosis, therapeutic intervention and monitoring response. Conventional contrast-enhanced MR neuroimaging using gadolinium (Gd) contrast agents primarily depicts disruption of the blood-brain barrier, demonstrating location and extent of disease, and also the morphological details at the lesion site. However, conventional imaging results do not always accurately predict tumour aggressiveness. Advanced functional MRI techniques such as dynamic contrast-enhanced perfusion-weighted imaging utilise contrast agents to convey physiological information regarding the haemodynamics and neoangiogenic status of the lesion that is often complementary to anatomical information obtained through conventional imaging. Most of the Gd contrast agents available have similar T1 and T2 relaxivities, and thus their contrast-enhancing capabilities are comparable. Exceptions are gadobenate-dimeglumine, Gd-EOB-DTPA, Gadobutrol and gadofosveset, which, owing to their transient-protein-binding capability, possess almost twice (and more) the T1 and T2 relaxivities as other agents at all magnetic field strengths. Numerous comparative studies have demonstrated the advantages of the increased relaxivity in terms of enhanced image contrast, image quality and diagnostic confidence. Here we summarise the benefits of higher relaxivity for the most common neuroimaging applications including MRI, perfusion-weighted imaging and MRA for evaluation of brain tumours, cerebrovascular disease and other CNS lesions.Keywords
This publication has 80 references indexed in Scilit:
- Brain Tumor Enhancement in Magnetic Resonance Imaging at 3 TeslaInvestigative Radiology, 2009
- Multicenter, double‐blind, randomized, intra‐individual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine in MRI of brain tumors at 3 teslaJournal of Magnetic Resonance Imaging, 2009
- Contrast-Enhanced MR Imaging of Brain Lesions: A Large-Scale Intraindividual Crossover Comparison of Gadobenate Dimeglumine versus GadodiamideAmerican Journal of Neuroradiology, 2008
- Perfusion Magnetic Resonance Imaging in PsychiatryTopics in Magnetic Resonance Imaging, 2008
- Evaluation of intraaxial enhancing brain tumors on magnetic resonance imaging: intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for visualization and assessment, and implications for surgical interventionJournal of Neurosurgery, 2007
- Comparison of contrast agents with high molarity and with weak protein binding in cerebral perfusion imaging at 3 TJournal of Magnetic Resonance Imaging, 2005
- Intraindividual comparison of 1.0 M gadobutrol and 0.5 M gadopentetate dimeglumine for time‐resolved contrast‐enhanced three‐dimensional magnetic resonance angiography of the upper torsoJournal of Magnetic Resonance Imaging, 2005
- Contrast-Enhanced Three-Dimensional Pulmonary Perfusion Magnetic Resonance ImagingInvestigative Radiology, 2004
- Intraindividual Comparison of Gadopentetate Dimeglumine, Gadobenate Dimeglumine, and Gadobutrol for Pelvic 3D Magnetic Resonance AngiographyInvestigative Radiology, 2003
- Acute human stroke studied by whole brain echo planar diffusion‐weighted magnetic resonance imagingAnnals of Neurology, 1995